Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CBLI Stock Summary
In the News

Cytocom, Inc. (CBLI) CEO Michael Handley on Q2 2021 Results - Earnings Call Transcript
Cytocom, Inc. (CBLI) CEO Michael Handley on Q2 2021 Results - Earnings Call Transcript

Cytocom, Inc. Reports Second Quarter 2021 Financial Results
FORT COLLINS, Colo., Aug. 16, 2021 /PRNewswire/ -- Cytocom, Inc. (Nasdaq: CBLI), a leading biopharmaceutical company creating next-generation immune therapies for serious medical conditions that induce immune restoration and homeostasis, today reported recent corporate updates and financial results for the Company for the second quarter ended June 30, 2021, a period of time prior to the completion of the merger between legacy Cleveland BioLabs and the formerly private Cytocom Inc. Following the completion of the merger on July 27, 2021, Cytocom, Inc. emerged as a publicly traded entity.

Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference
FORT COLLINS, Colo., Aug. 11, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the company will participate at the Empowering the Kingdom through Business Conference hosted by the Liberty University School of Business on August 10-12, 2021.

Cytocom, Inc. to Report Second Quarter 2021 Financial Results
FORT COLLINS, Colo., Aug. 10, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the Company will host a conference call and live audio webcast on Monday, August 16, 2021, at 8:30 a.m.

Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19
FORT COLLINS, Colo., Aug. 9, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided an update regarding its portfolio of clinical programs.

Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs
FORT COLLINS, Colo., Aug. 5, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided shareholders with an update regarding its recent merger with Cleveland BioLabs.

Cytocom, Inc. Receives Commitments for $90 Million in Equity and Debt Financing
FORT COLLINS, Colo., July 29, 2021 /PRNewswire/ -- Cytocom, Inc., (NASDAQ: CBLI), a leading biopharmaceutical company developing next generation therapies that focus on immune homeostasis, has secured agreements for $90 million in committed capital.

Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger
FORT COLLINS, Colo. and BUFFALO, N.Y.

CBLI Stock Price Increases Over 15% Pre-Market: Why It Happened
The stock price of Cleveland BioLabs, Inc. (Nasdaq: CBLI) increased by over 15% pre-market. This is why it happened.

Cleveland BioLabs, Inc. and Cytocom Announce Registration Statement and Proxy Statement for Previously Announced Merger Declared Effective by SEC
FORT COLLINS, Colo. and BUFFALO, N.Y.
CBLI Financial details
CBLI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2020-12-31
Metric | History | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0.32 | 0.17 | 0.1 | 0.1 | 0.02 | |
Net income per share | -0.24 | -0.87 | -0.32 | -0.23 | -0.19 | |
Operating cash flow per share | -0.46 | -0.59 | -0.41 | -0.24 | -0.19 | |
Free cash flow per share | -0.46 | -0.59 | -0.41 | -0.24 | -0.19 | |
Cash per share | 1.39 | 0.79 | 0.36 | 0.14 | 0.18 | |
Book value per share | 1.17 | 0.66 | 0.32 | 0.09 | 0.16 | |
Tangible book value per share | 1.17 | 0.66 | 0.32 | 0.09 | 0.16 | |
Share holders equity per share | 1.17 | 0.66 | 0.32 | 0.09 | 0.16 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0.21 | |
Market cap | 15.6M | 44.88M | 11.41M | 6.8M | 42.77M | |
Enterprise value | 8.7M | 40.65M | 7.79M | 5.68M | 40.82M | |
P/E ratio | -5.87 | -4.62 | -3.16 | -2.57 | -17.83 | |
Price to sales ratio | 4.43 | 23.04 | 10.02 | 6.11 | 162.65 | |
POCF ratio | -3.1 | -6.79 | -2.47 | -2.55 | -18.02 | |
PFCF ratio | -3.09 | -6.78 | -2.46 | -2.55 | -18.02 | |
P/B Ratio | 1.21 | 6.06 | 3.16 | 6.91 | 21.24 | |
PTB ratio | 1.21 | 6.06 | 3.16 | 6.91 | 21.24 | |
EV to sales | 2.47 | 20.86 | 6.84 | 5.1 | 155.25 | |
Enterprise value over EBITDA | -3.35 | -4.2 | -2.17 | -2.16 | -17.1 | |
EV to operating cash flow | -1.73 | -6.15 | -1.69 | -2.13 | -17.2 | |
EV to free cash flow | -1.72 | -6.14 | -1.68 | -2.13 | -17.2 | |
Earnings yield | -0.17 | -0.22 | -0.32 | -0.39 | -0.06 | |
Free cash flow yield | -0.32 | -0.15 | -0.41 | -0.39 | -0.06 | |
Debt to equity | 0.24 | 0.3 | 0.25 | 1.07 | 0.15 | |
Debt to assets | 0.19 | 0.23 | 0.2 | 0.52 | 0.13 | |
Net debt to EBITDA | 2.66 | 0.44 | 1.01 | 0.43 | 0.82 | |
Current ratio | 5.11 | 4.33 | 4.91 | 1.9 | 7.6 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 1.9 | 0.68 | 1.28 | 1.01 | 0.99 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.96 | 1.28 | 2.04 | 1.63 | 8.21 | |
Research and developement to revenue | 1.85 | 2.59 | 3.18 | 1.49 | 2.63 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0.01 | 0 | 0 | |
Capex to revenue | 0 | 0 | -0.02 | 0 | 0 | |
Capex to depreciation | -0.16 | -0.21 | -1.53 | -0.11 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0.05 | |
Graham number | 2.52 | 3.59 | 1.52 | 0.68 | 0.84 | |
ROIC | -3.5 | -5.79 | 1.69 | 4.93 | 1.48 | |
Return on tangible assets | -0.17 | -1.01 | -0.8 | -1.3 | -1.03 | |
Graham Net | 1.13 | 0.62 | 0.3 | 0.07 | 0.16 | |
Working capital | 12.78M | 7.37M | 3.56M | 950.11K | 2.01M | |
Tangible asset value | 12.85M | 7.41M | 3.61M | 984.29K | 2.01M | |
Net current asset value | 12.78M | 7.36M | 3.56M | 950.11K | 2.01M | |
Invested capital | 0 | 0 | 0 | 0 | 1.31 | |
Average receivables | 491.89K | 453.58K | 403.16K | 315.36K | 195.19K | |
Average payables | 266.78K | 268.92K | 170.26K | 201.35K | 215.67K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 36.59 | 103.87 | 80.76 | 124.2 | 15.98 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 9.98 | 3.51 | 4.52 | 2.94 | 22.84 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.21 | -1.31 | -1 | -2.69 | -1.19 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2021-06-30 for Q2
Metric | History | 2020-06-30 | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 |
---|---|---|---|---|---|---|
Revenue per share | 0.01 | 0 | 0 | 0 | 0 | |
Net income per share | -0.03 | -0.06 | -0.05 | -0.04 | -0.04 | |
Operating cash flow per share | -0.04 | -0.05 | -0.06 | -0.03 | -0.06 | |
Free cash flow per share | -0.04 | -0.05 | -0.06 | -0.03 | -0.06 | |
Cash per share | 0.32 | 0.23 | 0.17 | 1.03 | 0.89 | |
Book value per share | 0.28 | 0.21 | 0.15 | 0.65 | 0.87 | |
Tangible book value per share | 0.28 | 0.21 | 0.15 | 1 | 0.87 | |
Share holders equity per share | 0.28 | 0.21 | 0.15 | 0.65 | 0.87 | |
Interest debt per share | 0 | 0 | 0.16 | 0 | 0 | |
Market cap | 30.7M | 25.61M | 44.86M | 74.69M | 84.67M | |
Enterprise value | 27.3M | 22.89M | 42.91M | 60.33M | 70.89M | |
P/E ratio | -20.76 | -8.59 | -16.14 | -34.7 | -32.1 | |
Price to sales ratio | 485.41 | 586.89 | 170602.11B | 0 | 0 | |
POCF ratio | -64.45 | -37.52 | -56.9 | -205.71 | -98.4 | |
PFCF ratio | -64.45 | -37.52 | -56.9 | -205.71 | -98.4 | |
P/B Ratio | 9.33 | 9.32 | 22.28 | 8.1 | 6.26 | |
PTB ratio | 9.33 | 9.32 | 22.28 | 8.1 | 6.26 | |
EV to sales | 431.51 | 524.54 | 163199.65B | 0 | 0 | |
Enterprise value over EBITDA | -74.38 | -30.95 | -62.01 | -112.52 | -107.69 | |
EV to operating cash flow | -57.29 | -33.54 | -54.43 | -166.16 | -82.39 | |
EV to free cash flow | -57.29 | -33.54 | -54.43 | -166.16 | -82.39 | |
Earnings yield | -0.01 | -0.03 | -0.02 | -0.01 | -0.01 | |
Free cash flow yield | -0.02 | -0.03 | -0.02 | 0 | -0.01 | |
Debt to equity | 0.24 | 0.18 | 0.15 | 0.06 | 0.02 | |
Debt to assets | 0.19 | 0.15 | 0.13 | 0.04 | 0.02 | |
Net debt to EBITDA | 9.29 | 3.68 | 2.81 | 26.78 | 20.93 | |
Current ratio | 5.17 | 6.66 | 7.6 | 28.36 | 45.98 | |
Interest coverage | 0 | -272.79 | 0 | 0 | 0 | |
Income quality | 1.29 | 0.92 | 1.13 | 0.67 | 1.3 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 7.67 | 16.01 | 2251.15B | 0 | 0 | |
Research and developement to revenue | 2.69 | 2.7 | 703.62B | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0.31 | 0 | 0 | 0 | |
Graham number | 0.44 | 0.52 | 0.43 | 0.74 | 0.92 | |
ROIC | 0.19 | 0.31 | 0.45 | 0.04 | 0.05 | |
Return on tangible assets | -0.09 | -0.23 | -0.3 | -0.04 | -0.05 | |
Graham Net | 0.26 | 0.2 | 0.15 | 0.99 | 0.87 | |
Working capital | 3.28M | 2.74M | 2.01M | 14.18M | 13.52M | |
Tangible asset value | 3.29M | 2.75M | 2.01M | 14.18M | 13.53M | |
Net current asset value | 3.28M | 2.74M | 2.01M | 14.18M | 13.52M | |
Invested capital | 0 | 0 | 1.06 | 0 | 0 | |
Average receivables | 290.49K | 190.88K | 73.36K | 5.76K | 0 | |
Average payables | 283.84K | 291.09K | 224.17K | 238.75K | 185.11K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 350.8 | 278.81 | 3940.34B | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0.26 | 0.32 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.11 | -0.27 | -0.35 | -0.06 | -0.05 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
CBLI Frequently Asked Questions
What is Cytocom, Inc. stock symbol ?
Cytocom, Inc. is a US stock , located in Buffalo of New york and trading under the symbol CBLI
What is Cytocom, Inc. stock quote today ?
Cytocom, Inc. stock price is $3.17 today.
Is Cytocom, Inc. stock public?
Yes, Cytocom, Inc. is a publicly traded company.